search
Back to results

Immediate Treatment Outcomes of b-CPAP vs Oxygen Therapy in Preterm Babies Presenting With RDS at KCMC

Primary Purpose

Respiratory Distress Syndrome in Premature Infant

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
bCPAP Arm
Oxygen Arm
Sponsored by
Kilimanjaro Christian Medical Centre, Tanzania
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Respiratory Distress Syndrome in Premature Infant

Eligibility Criteria

28 Weeks - 37 Weeks (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • All preterm babies (< 37 weeks of gestation determined using Finnstorm score) presenting with signs of RDS (tachypnea of >60breaths /min, intercostal and subcostal recessions, nasal flaring, grunting and cyanosis)

Exclusion Criteria:

  • Preterm babies with birthweight less than 1kg (bCPAP machine can only be used in babies with body weight of 1-10kg)
  • Congenital malformations (cleft palate and lip, tracheal esophageal fistula and diaphragmatic hernia)
  • Mothers who refused to consent

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Other

    Arm Label

    bCPAP Arm.

    Oxygen Arm

    Arm Description

    Babies randomized to receive bCPAP were started (by principle investigator assisted by a clinician) on bCPAP (Rice 360◦c low cost bCPAP device) consisting of 3 components: (i) An oxygen concentrator with a gas flow fate of 3-4L/min, (ii) A nasal interface (short nasal prongs) connecting the baby's airway to a two limb circuit i.e the inspiratory limb connected to the bCPAP machine and the expiratory limb connected to the water bottle and (iii) An expiratory limb with the distal end submerged 6cm in water to generate an end expiratory pressure as seen in appendix 7. adopted from suppliers of the pumani bCPAP machine in Kenya.

    Preterms on the control arm and those whose parents didn't consent received the standard treatment for RDS i.e pure oxygen via nasal prongs from the oxygen cylinders.

    Outcomes

    Primary Outcome Measures

    Comparing the number of babies that survived with bCPAP treatment versus Oxygen therapy
    The proportion of babies discharged alive in the bCPAP arm versus the oxygen therapy arm.

    Secondary Outcome Measures

    Treatment duration
    The time spent on the allocated treatment arm till RDS symptoms (tachypnea (>60breaths/min), intercostal and subcostal recessions, nasal flaring, grunting and cyanosis) resolve.
    Duration of hospital stay
    Time from admission into the neonatal ward to discharge (dead or alive).
    Treatment complications
    Whilst the subject is receiving treatment, the following complications will be observed and recorded; like pneumothorax, nasal bleeding, injury to the skin, nose or eye, aspiration pneumonia, vomiting and any other complication considered related to the treatment as per the principal investigator's clinical judgement.

    Full Information

    First Posted
    July 2, 2018
    Last Updated
    August 3, 2018
    Sponsor
    Kilimanjaro Christian Medical Centre, Tanzania
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03620448
    Brief Title
    Immediate Treatment Outcomes of b-CPAP vs Oxygen Therapy in Preterm Babies Presenting With RDS at KCMC
    Official Title
    Immediate Treatment Outcomes of Bubble-cpap Versus Oxygen Therapy in Preterm Babies Presenting With Respiratory Distress Syndrome at Kilimanjaro Christian Medical Center
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2018
    Overall Recruitment Status
    Completed
    Study Start Date
    December 15, 2016 (Actual)
    Primary Completion Date
    May 15, 2017 (Actual)
    Study Completion Date
    May 15, 2017 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Kilimanjaro Christian Medical Centre, Tanzania

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    Yes
    Device Product Not Approved or Cleared by U.S. FDA
    Yes
    Product Manufactured in and Exported from the U.S.
    Yes

    5. Study Description

    Brief Summary
    Bubble - Continuous positive airway pressure (CPAP) has been reported to be effective, cheaper, simpler and more accessible compared to mechanical ventilator and surfactant treatment for preterms with respiratory distress syndrome in the neighbouring countries. This study aims to implement and determine the effectiveness of bCPAP and its immediate outcomes compared to oxygen therapy in preterm babies presenting with respiratory distress syndrome (RDS).
    Detailed Description
    Effective treatment of preterm babies with RDS requires exogenous surfactant and/or mechanical ventilation but these are of limited availability in developing countries. bCPAP is generated by exhalation against a constant opening pressure that produces positive end-expiratory pressure. This in-turn helps in maintaining lung volume at the end of expiration, preventing atelectasis, improving oxygenation, reducing respiratory fatigue and eventually preventing respiratory failure. bCPAP (Rice 360◦c low cost bCPAP device) consisting of 3 components: : (i)An air compressor connected to an oxygen concentrator with a gas flow fate of 3-4 L/min; (ii) A nasal interface (short nasal prongs) connecting the baby's airway to a two limb circuit i.e the inspiratory limb connected to the bCPAP machine and the expiratory limb connected to the water bottle and; (iii) An expiratory limb with the distal end submerged 6 cm in water to generate an end expiratory pressure At the neonatal unit at Kilimanjaro Christian Medical Center (KCMC), the standard of care for Preterm babies with RDS is receiving oxygen therapy via nasal prongs from oxygen cylinders.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Respiratory Distress Syndrome in Premature Infant

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    48 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    bCPAP Arm.
    Arm Type
    Experimental
    Arm Description
    Babies randomized to receive bCPAP were started (by principle investigator assisted by a clinician) on bCPAP (Rice 360◦c low cost bCPAP device) consisting of 3 components: (i) An oxygen concentrator with a gas flow fate of 3-4L/min, (ii) A nasal interface (short nasal prongs) connecting the baby's airway to a two limb circuit i.e the inspiratory limb connected to the bCPAP machine and the expiratory limb connected to the water bottle and (iii) An expiratory limb with the distal end submerged 6cm in water to generate an end expiratory pressure as seen in appendix 7. adopted from suppliers of the pumani bCPAP machine in Kenya.
    Arm Title
    Oxygen Arm
    Arm Type
    Other
    Arm Description
    Preterms on the control arm and those whose parents didn't consent received the standard treatment for RDS i.e pure oxygen via nasal prongs from the oxygen cylinders.
    Intervention Type
    Device
    Intervention Name(s)
    bCPAP Arm
    Intervention Description
    bCPAP (Rice 360◦c low cost bCPAP device)
    Intervention Type
    Other
    Intervention Name(s)
    Oxygen Arm
    Intervention Description
    Oxygen therapy from oxygen cylinders
    Primary Outcome Measure Information:
    Title
    Comparing the number of babies that survived with bCPAP treatment versus Oxygen therapy
    Description
    The proportion of babies discharged alive in the bCPAP arm versus the oxygen therapy arm.
    Time Frame
    6 months
    Secondary Outcome Measure Information:
    Title
    Treatment duration
    Description
    The time spent on the allocated treatment arm till RDS symptoms (tachypnea (>60breaths/min), intercostal and subcostal recessions, nasal flaring, grunting and cyanosis) resolve.
    Time Frame
    6 months
    Title
    Duration of hospital stay
    Description
    Time from admission into the neonatal ward to discharge (dead or alive).
    Time Frame
    6 months
    Title
    Treatment complications
    Description
    Whilst the subject is receiving treatment, the following complications will be observed and recorded; like pneumothorax, nasal bleeding, injury to the skin, nose or eye, aspiration pneumonia, vomiting and any other complication considered related to the treatment as per the principal investigator's clinical judgement.
    Time Frame
    6 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    28 Weeks
    Maximum Age & Unit of Time
    37 Weeks
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: All preterm babies (< 37 weeks of gestation determined using Finnstorm score) presenting with signs of RDS (tachypnea of >60breaths /min, intercostal and subcostal recessions, nasal flaring, grunting and cyanosis) Exclusion Criteria: Preterm babies with birthweight less than 1kg (bCPAP machine can only be used in babies with body weight of 1-10kg) Congenital malformations (cleft palate and lip, tracheal esophageal fistula and diaphragmatic hernia) Mothers who refused to consent

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes
    IPD Sharing Plan Description
    De-identified participant data will be shared as per the local country guidelines.
    IPD Sharing Time Frame
    Data will be made available 12 months after study completion.
    IPD Sharing Access Criteria
    Persons requesting data will be asked to sign a data transfer agreement as well as provide evidence of ethical clearance.
    Citations:
    PubMed Identifier
    24489715
    Citation
    Kawaza K, Machen HE, Brown J, Mwanza Z, Iniguez S, Gest A, Smith EO, Oden M, Richards-Kortum RR, Molyneux E. Efficacy of a low-cost bubble CPAP system in treatment of respiratory distress in a neonatal ward in Malawi. PLoS One. 2014 Jan 29;9(1):e86327. doi: 10.1371/journal.pone.0086327. eCollection 2014.
    Results Reference
    result

    Learn more about this trial

    Immediate Treatment Outcomes of b-CPAP vs Oxygen Therapy in Preterm Babies Presenting With RDS at KCMC

    We'll reach out to this number within 24 hrs